CureVac may let contractors make rival vaccines if own shot fails -CEO
By Tilman Blasshofer and Ludwig Burger
FRANKFURT, June 17 (Reuters) - German biotech firm CureVac 5CV.DE could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday.
The German company saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting investor confidence in its ability to take on rival shots.
"At the moment we are of course fully committed to obtain authorisation, the data will show," CureVac CEO Franz-Werner Haas told Reuters TV, referring to a final read-out that is still pending.
"If this capacity is not to be used - we are working with a whole network of outstanding partners - ... these partners would of course be free to make other products if we don't have a product," he said.
CureVac's manufacturing partners include Celonic Group of Switzerland, Novartis NOVN.S , Bayer BAYGn.DE , Fareva, Wacker WCHG.DE and Rentschler Biopharma SE.
However, Haas stressed that CureVac's efforts to develop a new generation of vaccines, a venture where it collaborates with GlaxoSmithKline GSK.L , would take precedence and that he would continue to draw on the external contractors for that drive
Drug supply chain expert Prashant Yadav said that if CureVac's partners were to make different mRNA vaccine, like Pfizer-BioNtech's PFE.N BNTX.O or Moderna's MRNA.O , it would take at least six to eight weeks to retool their facilities.
Yadav suggested that the Pfizer-BioNTech vaccine might be a better candidate, given that BioNTech is in Germany and many of CureVac's manufacturing partners are in Germany and Austria.
CureVac fails in pivotal COVID-19 vaccine trial with 47%
CureVac crashes after COVID-19 vaccine underwhelms BREAKINGVIEWS-CureVac’s pain may not yet have peaked
Reporting by Tilman Blasshofer, Ludwig Burger and Patricia Weiss; Editing by Pravin Char and Richard Chang
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.